Surgery of Colorectal Liver Metastases Involving the Inferior Vena Cava: A Systematic Review.
Mario Serradilla MartínJosé Ramón Oliver GuillénPablo Ruíz-QuijanoAna Palomares-CanoRoberto de la Plaza-LlamasJosé Manuel RamiaPublished in: Cancers (2023)
Combined hepatic and inferior vena cava (IVC) resection is the only potentially curative treatment for patients with colorectal liver metastases (CRLM) involving the IVC. Most of the existing data come from case reports or small case series. In this paper, a systematic review based on the PICO strategy was performed in accordance with the PRISMA statement. Papers from January 1980 to December 2022 were searched in Embase, PubMed, and the Cochrane Library databases. Articles considered for inclusion had to present data on simultaneous liver and IVC resection for CRLM and report surgical and/or oncological outcomes. From a total of 1175 articles retrieved, 29, including a total of 188 patients, met the inclusion criteria. The mean age was 58.3 ± 10.8 years. The most frequent techniques used were right hepatectomy ± caudate lobe for hepatic resections (37.8%), lateral clamping (44.8%) for vascular control, and primary closure (56.8%) for IVC repair. The thirty-day mortality reached 4.6%. Tumour relapse was reported in 65.8% of the cases. The median overall survival (OS) was 34 months (with a confidence interval of 30-40 months), and the 1-year, 3-year, and 5-year OS were 71.4%, 19.8%, and 7.1%, respectively. In the absence of prospective randomized studies, which are difficult to perform, IVC resection seems to be safe and feasible.
Keyphrases
- inferior vena cava
- liver metastases
- pulmonary embolism
- vena cava
- end stage renal disease
- minimally invasive
- big data
- electronic health record
- chronic kidney disease
- prognostic factors
- newly diagnosed
- ejection fraction
- free survival
- rectal cancer
- case report
- cardiovascular disease
- prostate cancer
- double blind
- coronary artery bypass
- acute coronary syndrome
- cardiovascular events
- type diabetes
- tyrosine kinase
- patient reported outcomes
- peritoneal dialysis
- machine learning
- combination therapy
- deep learning
- phase ii
- case control
- artificial intelligence